Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Addenbrookes Hospital, Cambridge
Studies from the United Kingdom and United States describe new findings in obesity research
May 8th, 2006
Investigators in the United Kingdom and United States have published new obesity data. Study 1: Sibutramine therapy in obese nondiabetic and diabetic patients should be continued for 3 months before predicting results. According to a study from England, "Early weight loss is generally considered to predict long-term weight outcome in obese patients, and this is reflected in prescribing guidelines for antiobesity drugs. For example, the current prescribing guidelines for the antiobesity drug, sibutramine, indicate that if patients have not lost 2 kg (or 4 lb) in the first 4 weeks of treatment with sibutramine 10 mg, the physician should re-evaluate...
Source: Biotech Week (2006-05-08)
|
